UB-311 Alzheimers vaccine is fully synthetic and employs the UBITh platform technologies to target aggregated forms of beta-amyloid.Read more...
Vaxxinity's UB-313 Migraine Vaccine candidate has entered into a Phase 1 clinical trial.Read more...
Vaxxinity UB-612 vaccine is designed to target a critical antigen from the S protein.Read more...
UB-621 is a first-in-class anti-gD monoclonal antibody. Read more...
Ultimovacs UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.Read more...
